Page last updated: 2024-12-08

cvt 124

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,3-dipropyl-8-(2-(5,6-epoxy)norbornyl)xanthine: CVT-124 is the (S)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID153990
SCHEMBL ID2825594
MeSH IDM0255728

Synonyms (8)

Synonym
1h-purine-2,6-dione, 3,7-dihydro-8-(1s,2r,4s,5s,6r)-3-oxatricyclo(3.2.1.02,4)oct-6-yl-1,3-dipropyl-
cvt 124
adentri
bg 9719
1,3-dipropyl-8-(2-(5,6-epoxy)norbornyl)xanthine
SCHEMBL2825594
8-[(1s,2r,4s,5s,6r)-3-oxatricyclo[3.2.1.02,4]octan-6-yl]-1,3-dipropyl-7h-purine-2,6-dione
AKOS040747769

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" These drug doses maximized survival duration in dose-response studies."( Adenosine A1 antagonism attenuates beta-adrenergic-resistant sudden hypoxic cardiac insufficiency.
Dalsey, WC; de Garavilla, L; Gao, E; Kaplan, JL; Victain, MS, 2005
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (29.41)18.2507
2000's12 (70.59)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.87 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index16.41 (26.88)
Search Engine Supply Index1.00 (0.95)

This Compound (27.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (11.11%)5.53%
Reviews3 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (72.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]